Vanrafia (atrasentan) PDUFA Date (Novartis)
FDA PDUFA decision date for Vanrafia (atrasentan) is April 2, 2025. Developed by Novartis. Indication: IgA nephropathy. Current status: Approved.
Indication
IgA nephropathy
Regulatory details
- Company: Novartis
- Therapeutic area: Nephrology
- Application type: NDA
- Review type: Priority
- PDUFA date: 2025-04-02
- Outcome: Approved